MiR-25-3p Serves As an Oncogenic MicroRNA by Downregulating the Expression of Merlin in Osteosarcoma

Overview

Journal Cancer Manag Res

Publisher Dove Medical Press

Specialty Oncology

Date 2020 Oct 16

PMID 33061594

Citations 7

Authors

Hua-Chun Rao

Zhao-Ke Wu

Si-da Wei

Yun Jiang

Qing-Xin Guo

Jia-Wen Wang

Chang-Xian Chen

Hui-Yong Yang

Affiliations

Soon will be listed here.

Abstract

Purpose: Moesin-ezrin-radixin-like protein (Merlin) has been identified as a tumor suppressor in several types of cancers. However, the biological function of Merlin in osteosarcoma remains unclear. MicroRNAs (miRNAs) can influence cancer progression by targeting oncogenes or anti-oncogenes. In this study, we sought to evaluate the regulation of Merlin expression by miR-25-3p and the role of the miR-25-3p/Merlin axis in osteosarcoma progression, with the aim of identifying a potential therapeutic target for osteosarcoma.

Materials And Methods: TCGA (The Cancer Genome Atlas) database was used to analyze the correlation between Merlin expression and prognosis. RT-qPCR and Western blotting analyses were performed to compare Merlin expression between normal and malignant cells. A dual-luciferase reporter assay was performed to evaluate the direct targeting of Merlin by miR-25-3p. We overexpressed miR-25-3p, or/and Merlin, in U-2 OS and 143B cells, and studied their cellular functions in vitro. MTT and colony formation assays were performed to determine the effects on cell growth. EdU and cell cycle assays were performed to analyze the effects in cell replication. We used annexin V-fluorescein isothiocyanate and propidium iodide to stain apoptotic cells, and analyzed the cells using flow cytometry. The effects on cell metastasis were studied in wound healing and transwell assays. Lastly, the underlying mechanism was determined in RT-qPCR and Western blotting experiments.

Results: Low Merlin expression was linked to poor prognosis. miR-25-3p was observed to directly target Merlin and downregulate its expression. miR-25-3p promoted cell growth, migration, and invasion, and inhibited apoptosis induced by cisplatin. Moreover, the overexpression of Merlin reversed the abovementioned effects of miR-25-3p. Further, the miR-25-3p/Merlin axis was observed to play an important role in the Hippo pathway, and regulated the expression of genes such as BIRC5, CTGF, and CYR61.

Conclusion: miR-25-3p functions as an oncogenic microRNA in osteosarcoma by targeting Merlin, and may serve as a potential therapeutic target for osteosarcoma.

Citing Articles

miR‑25‑3p serves as an oncogenic in colorectal cancer cells by regulating the ubiquitin ligase FBXW7 function.

Chen Y, Chen B, Tu S, Yuan H Oncol Rep. 2024; 52(5).

PMID: 39329268 PMC: 11450686. DOI: 10.3892/or.2024.8812.

The biological interplay between air pollutants and miRNAs regulation in cancer.

Giammona A, Remedia S, Porro D, Lo Dico A, Bertoli G Front Cell Dev Biol. 2024; 12:1343385.

PMID: 38434617 PMC: 10905188. DOI: 10.3389/fcell.2024.1343385.

CSNK1D-mediated phosphorylation of HNRNPA2B1 induces miR-25-3p/miR-93-5p maturation to promote prostate cancer cell proliferation and migration through mA-dependent manner.

Qi F, Shen W, Wei X, Cheng Y, Xu F, Zheng Y Cell Mol Life Sci. 2023; 80(6):156.

PMID: 37208565 PMC: 11072693. DOI: 10.1007/s00018-023-04798-5.

Ezrin expression in female reproductive tissues: A review of regulation and pathophysiological implications.

Xu W, Shi L, Xu J, Qian H, Zhou H, Wang L Front Cell Dev Biol. 2023; 11:1125881.

PMID: 36968198 PMC: 10030596. DOI: 10.3389/fcell.2023.1125881.

CircHSPG2 absence weakens hypoxia-induced dysfunction in cardiomyocytes by targeting the miR-25-3p/PAWR axis.

Zhao Y, Wang S, Liu S, Yan Q, Li Y, Liu Y Cardiovasc Diagn Ther. 2022; 12(5):589-602.

PMID: 36329956 PMC: 9622406. DOI: 10.21037/cdt-22-197.

References

Hamaratoglu F, Willecke M, Kango-Singh M, Nolo R, Hyun E, Tao C . The tumour-suppressor genes NF2/Merlin and Expanded act through Hippo signalling to regulate cell proliferation and apoptosis. Nat Cell Biol. 2005; 8(1):27-36. DOI: 10.1038/ncb1339. View

Feng S, Pan W, Jin Y, Zheng J . MiR-25 promotes ovarian cancer proliferation and motility by targeting LATS2. Tumour Biol. 2014; 35(12):12339-44. DOI: 10.1007/s13277-014-2546-0. View

Zeng Z, Li Y, Pan Y, Lan X, Song F, Sun J . Cancer-derived exosomal miR-25-3p promotes pre-metastatic niche formation by inducing vascular permeability and angiogenesis. Nat Commun. 2018; 9(1):5395. PMC: 6300604. DOI: 10.1038/s41467-018-07810-w. View

Fan S, Liang Z, Gao Z, Pan Z, Han S, Liu X . Identification of the key genes and pathways in prostate cancer. Oncol Lett. 2018; 16(5):6663-6669. PMC: 6202544. DOI: 10.3892/ol.2018.9491. View

Grignani G, Palmerini E, Ferraresi V, DAmbrosio L, Bertulli R, Asaftei S . Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. Lancet Oncol. 2014; 16(1):98-107. DOI: 10.1016/S1470-2045(14)71136-2. View

Chen H, Pan H, Qian Y, Zhou W, Liu X . MiR-25-3p promotes the proliferation of triple negative breast cancer by targeting BTG2. Mol Cancer. 2018; 17(1):4. PMC: 5759260. DOI: 10.1186/s12943-017-0754-0. View

Lai D, Ho K, Hao Y, Yang X . Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF. Cancer Res. 2011; 71(7):2728-38. DOI: 10.1158/0008-5472.CAN-10-2711. View

Ning L, Zhang M, Zhu Q, Hao F, Shen W, Chen D . miR-25-3p inhibition impairs tumorigenesis and invasion in gastric cancer cells and . Bioengineered. 2020; 11(1):81-90. PMC: 6961587. DOI: 10.1080/21655979.2019.1710924. View

Osborne T, Khanna C . A review of the association between osteosarcoma metastasis and protein translation. J Comp Pathol. 2012; 146(2-3):132-42. PMC: 3496179. DOI: 10.1016/j.jcpa.2011.12.007. View

10.

Wu T, Hu H, Zhang T, Jiang L, Li X, Liu S . miR-25 Promotes Cell Proliferation, Migration, and Invasion of Non-Small-Cell Lung Cancer by Targeting the LATS2/YAP Signaling Pathway. Oxid Med Cell Longev. 2019; 2019:9719723. PMC: 6604298. DOI: 10.1155/2019/9719723. View

11.

Wang W, Luo Y . MicroRNAs in breast cancer: oncogene and tumor suppressors with clinical potential. J Zhejiang Univ Sci B. 2015; 16(1):18-31. PMC: 4288941. DOI: 10.1631/jzus.B1400184. View

12.

Horiguchi A, Zheng R, Shen R, Nanus D . Inactivation of the NF2 tumor suppressor protein merlin in DU145 prostate cancer cells. Prostate. 2008; 68(9):975-84. DOI: 10.1002/pros.20760. View

13.

Gulino R, Forte S, Parenti R, Memeo L, Gulisano M . MicroRNA and pediatric tumors: Future perspectives. Acta Histochem. 2015; 117(4-5):339-54. DOI: 10.1016/j.acthis.2015.02.007. View

14.

Lee J, Kim H, Ryu C, Kim J, Choi B, Lim Y . Merlin, a tumor suppressor, interacts with transactivation-responsive RNA-binding protein and inhibits its oncogenic activity. J Biol Chem. 2004; 279(29):30265-73. DOI: 10.1074/jbc.M312083200. View

15.

Felley-Bosco E, Stahel R . Hippo/YAP pathway for targeted therapy. Transl Lung Cancer Res. 2015; 3(2):75-83. PMC: 4367659. DOI: 10.3978/j.issn.2218-6751.2014.02.03. View

16.

Pan D . The hippo signaling pathway in development and cancer. Dev Cell. 2010; 19(4):491-505. PMC: 3124840. DOI: 10.1016/j.devcel.2010.09.011. View

17.

Yin F, Yu J, Zheng Y, Chen Q, Zhang N, Pan D . Spatial organization of Hippo signaling at the plasma membrane mediated by the tumor suppressor Merlin/NF2. Cell. 2013; 154(6):1342-55. PMC: 3835333. DOI: 10.1016/j.cell.2013.08.025. View

18.

Rausch V, Hansen C . The Hippo Pathway, YAP/TAZ, and the Plasma Membrane. Trends Cell Biol. 2019; 30(1):32-48. DOI: 10.1016/j.tcb.2019.10.005. View

19.

Zhang H, Geng D, Gao J, Qi Y, Shi Y, Wang Y . Expression and significance of Hippo/YAP signaling in glioma progression. Tumour Biol. 2016; 37:15665–15676. DOI: 10.1007/s13277-016-5318-1. View

20.

Glover J, Krailo M, Tello T, Marina N, Janeway K, Barkauskas D . A summary of the osteosarcoma banking efforts: a report from the Children's Oncology Group and the QuadW Foundation. Pediatr Blood Cancer. 2015; 62(3):450-5. PMC: 4304398. DOI: 10.1002/pbc.25346. View